⚗️ This collaboration aims to speed up the development of innovative therapies for degenerative diseases.
🔬 RoosterBio’s hMSC products combined with Thermo Fisher’s GMP contract manufacturing will enhance production capabilities.
🚀 The partnership will help biopharmaceutical companies streamline clinical trial material production.
Introduction:
The collaboration between RoosterBio and Thermo Fisher Scientific symbolizes a strategic alliance aimed at enhancing the manufacturing processes for cell and exosome therapies, which are critical for developing treatments for degenerative diseases.
- RoosterBio specializes in providing adult human mesenchymal stem/stromal cells (hMSCs) and related bioprocess development services.
- The partnership leverages RoosterBio’s innovative product offerings in hMSCs and Thermo Fisher’s expertise in GMP contract manufacturing.
- Thermo Fisher will provide diverse manufacturing services, including the expansion and purification of hMSCs and exosomes, along with drug product manufacturing.
- The collaboration aims to accelerate timelines for clinical trial material production for biopharmaceutical companies.
- This partnership is expected to enhance the development of engineered cell and exosome therapies by combining proven technologies with scalable manufacturing capabilities.
Conclusion:
The strategic collaboration between RoosterBio and Thermo Fisher Scientific is poised to significantly advance the field of cell and exosome therapies, directly impacting the treatment landscape for degenerative diseases. By merging their respective strengths, the companies aim to improve the efficiency of biopharmaceutical manufacturing processes, facilitating faster access to critical therapies for patients.
